Protective Effects of Liraglutide and Linagliptin in Celegans as a New Model for Glucose-Induced Neurodegeneration

Hormone and Metabolic Research

Volumn 48, Issue 1, 2015, Pages 70-75

  Wongchai, K ^a   Schlotterer, A ^a   Lin, J ^a   Humpert, P M ^b   Klein, T ^c   Hammes, H P ^a   Morcos, M ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Stoffwechselzentrum Rhein Pfalz   (Germany)

^c Metabolic Diseases   (Germany)

Author keywords

diabetic complications; DPP 4; GLP 1; neuroprotective effects

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AKT-1 PROTEIN, C ELEGANS; ANTIOXIDANT; CAENORHABDITIS ELEGANS PROTEIN; DAF-16 PROTEIN, C ELEGANS; FORKHEAD TRANSCRIPTION FACTOR; GLUCOSE; LINAGLIPTIN; LIRAGLUTIDE; METHYLGLYOXAL; NEUROPROTECTIVE AGENT; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE;

ANIMAL; BIOLOGICAL MODEL; CAENORHABDITIS ELEGANS; DOSE RESPONSE; DRUG EFFECTS; LONGEVITY; METABOLISM; NERVE DEGENERATION; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORKHEAD TRANSCRIPTION FACTORS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; LINAGLIPTIN; LIRAGLUTIDE; LONGEVITY; MODELS, BIOLOGICAL; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVALDEHYDE; REACTIVE OXYGEN SPECIES;

EID: 84955344581     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0035-1549876     Document Type: Article

References (44)

1. Feng Y., Busch S., Gretz N., Hoffmann S., Hammes H. P. Crosstalk in the retinal neurovascular unit - lessons for the diabetic retina. Exp Clin Endocrinol Diabetes: 2012; 120 199 201
2. McClean P. L., Parthsarathy V., Faivre E., Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci: 2011; 31 6587 6594
3. Holst J. J., Burcelin R., Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin: 2011; 27 547 558
4. Trumper K., Trumper A., Trusheim H., Arnold R., Goke B., Horsch D. Integrative mitogenic role of protein kinase B/Akt in beta-cells. Ann N Y Acad Sci: 2000; 921 242 250
5. Fatrai S., Elghazi L., Balcazar N., Cras-Meneur C., Krits I., Kiyokawa H., Bernal-Mizrachi E. Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes: 2006; 55 318 325
6. Peshavaria M., Larmie B. L., Lausier J., Satish B., Habibovic A., Roskens V., Larock K., Everill B., Leahy J. L., Jetton T. L. Regulation of pancreatic beta-cell regeneration in the normoglycemic 60% partial-pancreatectomy mouse. Diabetes: 2006; 55 3289 3298
7. Wang Q., Li L., Xu E., Wong V., Rhodes C., Brubaker P. L. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia: 2004; 47 478 487
8. Wrede C. E., Dickson L. M., Lingohr M. K., Briaud I., Rhodes C. J. Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J Biol Chem: 2002; 277 49676 49684
9. Gaglia M. M., Kenyon C. Stimulation of movement in a quiescent, hibernation-like form of Caenorhabditis elegans by dopamine signaling. J Neurosci: 2009; 29 7302 7314
10. Byrne A. B., Walradt T., Gardner K. E., Hubbert A., Reinke V., Hammarlund M. Insulin/IGF1 signaling inhibits age-dependent axon regeneration. Neuron: 2014; 81 561 573
11. Batchuluun B., Inoguchi T., Sonoda N., Sasaki S., Inoue T., Fujimura Y., Miura D., Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis: 2014; 232 156 164
12. Filippatos T. D., Elisaf M. S. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes: 2013; 4 190 201
13. Shiraki A., Oyama J., Komoda H., Asaka M., Komatsu A., Sakuma M., Kodama K., Sakamoto Y., Kotooka N., Hirase T., Node K. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis: 2012; 221 375 382
14. Agrawal R., Jain P., Dikshit S. N. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor. Curr Drug Targets: 2012; 13 970 983
15. Steinbrecher A., Reinhold D., Quigley L., Gado A., Tresser N., Izikson L., Born I., Faust J., Neubert K., Martin R., Ansorge S., Brocke S. Dipeptidyl peptidase IV in inflammatory CNS disease. Adv Exp Med Biol: 2000; 477 145 153
16. Preller V., Gerber A., Wrenger S., Togni M., Marguet D., Tadje J., Lendeckel U., Rocken C., Faust J., Neubert K., Schraven B., Martin R., Ansorge S., Brocke S., Reinhold D. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol: 2007; 178 4632 4640
17. Reinhold D., Biton A., Pieper S., Lendeckel U., Faust J., Neubert K., Bank U., Tager M., Ansorge S., Brocke S. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacol: 2006; 6 1935 1942
18. Steinbrecher A., Reinhold D., Quigley L., Gado A., Tresser N., Izikson L., Born I., Faust J., Neubert K., Martin R., Ansorge S., Brocke S. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol: 2001; 166 2041 2048
19. Rohnert P., Schmidt W., Emmerlich P., Goihl A., Wrenger S., Bank U., Nordhoff K., Tager M., Ansorge S., Reinhold D., Striggow F. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflam: 2012; 9 44
20. Kroller-Schon S., Knorr M., Hausding M., Oelze M., Schuff A., Schell R., Sudowe S., Scholz A., Daub S., Karbach S., Kossmann S., Gori T., Wenzel P., Schulz E., Grabbe S., Klein T., Munzel T., Daiber A. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res: 2012; 96 140 149
21. Mendler M., Schlotterer A., Morcos M., Nawroth P. P. Understanding diabetic polyneuropathy and longevity: what can we learn from the nematode Caenorhabditis elegans? Exp Clin Endocrinol Diabetes: 2012; 120 182 183
22. Schlotterer A., Kukudov G., Bozorgmehr F., Hutter H., Du X., Oikonomou D., Ibrahim Y., Pfisterer F., Rabbani N., Thornalley P., Sayed A., Fleming T., Humpert P., Schwenger V., Zeier M., Hamann A., Stern D., Brownlee M., Bierhaus A., Nawroth P., Morcos M. C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes: 2009; 58 2450 2456
23. Thorpe S. R., Baynes J. W. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging: 1996; 9 69 77
24. Morcos M., Du X., Pfisterer F., Hutter H., Sayed A. A., Thornalley P., Ahmed N., Baynes J., Thorpe S., Kukudov G., Schlotterer A., Bozorgmehr F., El Baki R. A., Stern D., Moehrlen F., Ibrahim Y., Oikonomou D., Hamann A., Becker C., Zeier M., Schwenger V., Miftari N., Humpert P., Hammes H. P., Buechler M., Bierhaus A., Brownlee M., Nawroth P. P. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell: 2008; 7 260 269
25. Hammes H. P., Federoff H. J., Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med: 1995; 1 527 534
26. Antonetti D. A., Klein R., Gardner T. W. Diabetic retinopathy. N Eng J Med: 2012; 366 1227 1239
27. Tehrani N., Del Rosario J., Dominguez M., Kalb R., Mano I. The insulin/IGF signaling regulators cytohesin/GRP-1 and PIP5K/PPK-1 modulate susceptibility to excitotoxicity in C. elegans. PloS One: 2014; 9 e113060
28. Schlotterer A., Hamann A., Kukudov G., Ibrahim Y., Heckmann B., Bozorgmehr F., Pfeiffer M., Hutter H., Stern D., Du X., Brownlee M., Bierhaus A., Nawroth P., Morcos M. Apurinic/apyrimidinic endonuclease 1, p53, and thioredoxin are linked in control of aging in C. elegans. Aging Cell: 2010; 9 420 432
29. Mendler M., Schlotterer A., Ibrahim Y., Kukudov G., Fleming T., Bierhaus A., Riedinger C., Schwenger V., Herzig S., Hecker M., Tyedmers J., Nawroth P. P., Morcos M. daf-16/FOXO and glod-4/glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in Caenorhabditis elegans. Diabetologia: 2015; 58 393 401
30. Abramoff M. D., Magelhaes P. J., Ram S. J. Image Processing with ImageJ. Biophotonics Int: 2004; 11 36 42
31. Wolkow C. A., Kimura K. D., Lee M. S., Ruvkun G. Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science: 2000; 290 147 150
32. Alcedo J., Kenyon C. Regulation of C. elegans longevity by specific gustatory and olfactory neurons. Neuron: 2004; 41 45 55
33. Knorr M., Schell R., Steven S., Heeren T., Schuff A., Oelze M., Schuhmacher S., Hausding M., Münzel T., Klein T., Daiber A. Comparison of Direct and Indirect Antioxidant Effects of Linagliptin (BI 1356, ONDERO) with other Gliptins - Evidence for Anti-inflammatory Properties of Linagliptin. Free Radical Biol Med: 2010; 49 S197
34. Kröller-Schuhmacher S., Knorr M., Oelze M., Schuff A., Hausding M., Schell R., Sudowe S., Scholz A., Daub S., Karbach S., Kossmann S., Schulz E., Gori T., Wenzel P., Klein T., Münzel T., Daiber A. Comparison of direct and indirect antioxidant effect of linagliptin with other gliptins - evidence for antioxidant and antiinflammatory properties of linagliptin. Vasc Pharmacol: 2012; 56 352
35. Parthsarathy V., Holscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PloS One: 2013; 8 e58784
36. Jee C., Lee J., Lim J. P., Parry D., Messing R. O., McIntire S. L. SEB-3, a CRF receptor-like GPCR, regulates locomotor activity states, stress responses and ethanol tolerance in Caenorhabditis elegans. Genes Brain Behav: 2013; 12 250 262
37. Frooninckx L., Van Rompay L., Temmerman L., Van Sinay E., Beets I., Janssen T., Husson S. J., Schoofs L. Neuropeptide GPCRs in C. elegans. Front Endocrinol: 2012; 3 167
38. Tsai T. H., Sun C. K., Su C. H., Sung P. H., Chua S., Zhen Y. Y., Leu S., Chang H. W., Yang J. L., Yip H. K. Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction. J Hypertens: 2015; 10.1097/HJH.0000000000000529
39. Gault V. A., Lennox R., Flatt P. R. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab: 2015; 17 403 413
40. Pintana H., Apaijai N., Chattipakorn N., Chattipakorn S. C. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol: 2013; 218 1 11
41. Darsalia V., Ortsater H., Olverling A., Darlof E., Wolbert P., Nystrom T., Klein T., Sjoholm A., Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes: 2013; 62 1289 1296
42. Yoshina S., Sakaki K., Yonezumi-Hayashi A., Gengyo-Ando K., Inoue H., Iino Y., Mitani S. Identification of a novel ADAMTS9/GON-1 function for protein transport from the ER to the Golgi. Mol Biol Cell: 2012; 23 1728 1741
43. Shimizu S., Hosooka T., Matsuda T., Asahara S., Koyanagi-Kimura M., Kanno A., Bartolome A., Etoh H., Fuchita M., Teruyama K., Takahashi H., Inoue H., Mieda Y., Hashimoto N., Seino S., Kido Y. DPP4 inhibitor vildagliptin preserves beta-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice. J Mol Endocrinol: 2012; 49 125 135
44. De Haes W., Frooninckx L., Van Assche R., Smolders A., Depuydt G., Billen J., Braeckman B. P., Schoofs L., Temmerman L. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc Natl Acad Sci USA: 2014; 111 E2501 E2509